Alzheimer’s diagnostics and therapeutics market was valued at approximately USD 7,100 million for 2017 and is expected to register a CAGR of approximately 6.7% during the forecast period of 2018-2023|Key Players - Roche, Novartis, Merck, Pfizer, Eisai,

The United States is the global leader in AD Intervention and Management

According to the Alzheimer’s Association, more than 5 million Americans are living with AD, as of 2017. The United States is considered as the global leader in Alzheimer’s disease intervention and management. The United States has a large pool of biopharmaceutical companies, which cumulatively have a total of 85 drugs in various stages in the pipeline for combating Alzheimer’s disease. The United States holds a major share of around 83% of the total revenue in North America (it has largest market share compare to other region).

Detailed Sample Copy of Updated Analysis @ https://marketprognosis.com/sample-request/17099
Note: “If this link doesn’t work in Internet Explorer, kindly try pasting it in other browsers.”

Alzheimer’s disease (AD) is one of the most prevalent dementia in the world. Early diagnosis of AD is challenging. Biomarkers improve the acurracy of diagnosis, so find application in drug development for AD. Investments in the development of biomarkers for drug development, increasing pipeline drug development, increasing incidence and prevalence of Alzheimer's disease, increasing sophisticated diagnostics for early detection precise drug development, and emerging novel diagnostic techniques and early detection of AD are acting as the major driver and fuelling the growth of the Alzheimer's disease diagnostics & therapeutics market globally.

Request Discount on this report @ https://marketprognosis.com/discount-request/17099
Note: “If this link doesn’t work in Internet Explorer, kindly try pasting it in other browsers.”

Market Segments:
Alzheimer’s diagnostics and therapeutics market is segmented by:
1. Therapeutics: Cholinesterase Inhibitors, NMDA Receptor Antagonists, Others
2. Diagnostics: Brain Imaging, CSF Test for AD
3. Geography: North America, South America, Europe, Asia Pacific, Middle East & Africa

Key Developments in the Market
• January 2018: Johnson & Johnson Innovation LLC and Janssen Pharmaceuticals Inc. (JPI) established an exclusive research collaboration with the University of Pennsylvania’s Gene Therapy Program.
• October 2017: Eisai and Biogen Inc. expanded their existing agreement to develop and commercialize investigation AD treatments jointly.

Enquiry before Buying @ https://marketprognosis.com/enquiry/17099
Note: “If this link doesn’t work in Internet Explorer, kindly try pasting it in other browsers.”

About Market Prognosis
We at Market Prognosis believe in giving a crystal clear view of market dynamics for achieving success in today's complex and competitive marketplace through our quantitative & qualitative research methods.
We help our clients identify the best market insights and analysis required for their business thus enabling them to take strategic and intelligent decision.
We believe in delivering actionable insights for your business growth and success.

Contact us:
ProgMark Pvt Ltd,
Thane - 421501
India.
Contact No: +1 973 241 5193
Email: sales@marketprognosis.com

This release was published on openPR.